Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.

Author: , ArribasJosé R, EronJoseph J, GatheJoseph, HufkensVeerle, LathouwersErkki, MolinaJean-Michel, NegredoEugenia, OpsomerMagda, OrkinChloe, PetrovicRomana, Van LanduytErika, VanveggelSimon

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Equivalence TrialA clinical trial designed to show that a new treatment is equivalent in efficacy/safety to an existing treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the efficacy and safety of switching to a single-tablet regimen of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide versus continuing a regimen of boosted protease inhibitor, emtricitabine, and tenofovir disoproxil fumarate in people living with HIV.
Paper Details　
Original Abstract of the Article :
Simplified regimens with reduced pill burden and fewer side-effects are desirable for people living with HIV. We investigated the efficacy and safety of switching to a single-tablet regimen of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide versus continuing a regimen of boosted prot...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S2352-3018(17)30179-0

データ提供：米国国立医学図書館（NLM）

Simplifying HIV Treatment: A Quest for a More Manageable Desert

The journey of managing HIV has evolved significantly with advancements in treatment. This study examines the efficacy and safety of switching from a complex regimen of boosted protease inhibitors, emtricitabine, and tenofovir disoproxil fumarate to a single-tablet regimen of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide. The researchers aimed to simplify treatment by reducing pill burden and potentially minimizing side effects.

A Single Tablet Regimen: A Potential Oasis in the Desert of HIV Treatment

The study found that switching to the single-tablet regimen was non-inferior to continuing the existing regimen in terms of efficacy. Moreover, the single-tablet regimen was associated with fewer side effects. These findings suggest that the single-tablet regimen offers a simplified and potentially more tolerable treatment option for individuals with HIV.

Navigating the Desert of HIV Management

The desert of HIV management can be a complex and demanding landscape. This study offers a glimmer of hope with the development of a simpler and potentially more tolerable treatment regimen. Continued research and innovation are essential to improving the lives of individuals with HIV, making the journey through this desert less challenging.

Dr. Camel's Conclusion

This study ventures into the desert of HIV treatment, seeking to simplify and improve the lives of individuals with this condition. The findings suggest that switching to a single-tablet regimen can be a positive step, offering a more manageable approach to treatment. Like a camel traversing a vast and unforgiving desert, researchers continue to seek solutions that make the journey less burdensome.

Date :
  1. Date Completed 2018-09-19
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

28993180

DOI: Digital Object Identifier

10.1016/S2352-3018(17)30179-0

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.